arrow
M

Margaret Macro

institut national de la santé et de la recherche médicale (inserm)
H指数:47
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Assessing the benefit of incorporating ananti-CD38 monoclonal antibody into second-or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study

评估将抗CD38单克隆抗体纳入复发/难治性多发性骨髓瘤患者二线或三线系统性治疗中的获益:法国真实世界EMMY研究的结果

2026-02-010
OAAI
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)

通过大型开放式网络课程(MOOC)为多发性骨髓瘤患者及照护者提供以患者为中心的教育:法国多发性骨髓瘤患者协会(AF3M)和法语骨髓瘤协作组(IFM)关于知识增长的描述性研究

2026-01-010
PRE
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Real-world utilization of carfilzomib (once or twice weekly) initiated in patients after a first relapse between 2017-2022 in France: an analysis from a large-scale Epidemiology of Multiple MYeloma (EmmY) cohort

2017-2022年间法国在首次复发后的多发性骨髓瘤患者中开始使用卡非佐米(每周一次或两次)的实时应用:来自大规模多发性骨髓瘤流行病学(EmmY)队列的分析

2025-08-070
OAAI
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study

抗CD38单克隆抗体在初诊多发性骨髓瘤患者一线治疗中的影响:来自EMMY研究的真实世界结果

2025-07-240
PRE
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT

移植不适格的套细胞瘤患者在使用三联/四联疗法时的血栓栓塞:BENEFIT研究的后续分析

2025-06-140
PRE
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

达拉妥单抗-硼替佐米-沙利度胺-地塞米松用于新诊断的骨髓瘤:CASSIOPEIA微小残留病结果

Blood
IF23.1
2025-03-260
OA
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study
2024-06-019
OA
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
LEUKEMIA
IF13.4
2024-04-272
OAAI
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
2023-11-304
OAAI
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
2023-11-024
OAAI
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
2023-10-2611
OAAI
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

ixazomib联合来那度胺和地塞米松在复发/难治性多发性骨髓瘤中的真实疗效: REMIX研究

2023-06-105
OAAI
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
2023-05-222
OA
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
2023-04-209
OAAI
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myelome study
2023-01-010
OA